A recent opinion article by Tara O'Neill Hayes outlines arguments for CMS' "Final 340B Rule." The Centers for Medicare and Medicaid Services greeted the new year by slashing what Medicare pays hospitals for specific drugs by up to 30 percent. Consequently, Hospitals are vehemently against this decision....
Recently, Congress introduced reformed 340B eligibility requirements and has requested more comprehensive reporting on how hospitals utilize savings from the program. Republican Representative Chris Collins initiated the legislative push to overhaul the 340B Drug Discount Program and expects prompt consideration on the House floor. Collins views...
Thirty years of claims processing experience makes SCL 340B CARE the ideal partner, providing an elite set of services for clients throughout the country. We are the leader in 340B program administration and continually build on this reputation through the constant expansion and excellence of...
The future of the 340B drug discount program is in jeopardy as the ongoing debate over the program intensifies. Initially, this program aimed to serve low-income patients with access to medications by requiring pharmaceutical companies to discount their drugs for providers. However, in recent years...
A recent report from the National Academies of Sciences, Engineering, and Medicine shows that the need for effective and affordable medicines is being underserved by the biopharmaceutical sector. The report is composed of eight (8) recommendations and twenty-seven (27) strategies aimed to improve prescription drug...
The future of the program is uncertain with the introduction of CMS’s 340B Final Rule Tension is rising between Pharmaceutical companies and providers as they continue to dispute the slashing of reimbursements for the 340B drug discount program. Fueling the debate is CMS’s decision to reduce payments...
The 340B Drug Pricing Program "mega-guidance" spends its third month at the OMB. It is suspected that contract pharmacy arrangements will see some revisions which will reduce duplicate discounts paid by manufacturers. In the past, HRSA planned to issue a "mega-reg" that would address contract pharmacy arrangements...
Our healthcare industry is evolving into a fee-for-value payment system, which promotes value and efficiency. This new system increases the quality of care and focuses on the outcome of treatment for its patients. This industry improvement is now encountering astronomical price increases of prescription drugs...
A select group of organizations in the health and human service field have a distinct market advantage , they are able to purchase medications for consumers at a greatly reduced price through the 340B Drug Pricing Program (340B Program). As we move towards more value-based...